Diabetes mellitus type prevention

Thl cells. Subpopulation of helper T lymphocytes producing mainly IL-2, IFN-y, and TNF-(5, thereby responsible for phagocyte-dependent host responses. Thl-dominated responses are seen in autoimmune diseases in which cytotoxic T cells and macrophages play a major role, e.g. multiple sclerosis, diabetes mellitus type 1, Hashimoto thyroiditis, and Crohn disease. Interestingly, switching from Thl to Th2 response can prevent Thl-mediated tissue destruction in animal models. 

Janssen J A, Lamberts SW. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus is prevention possible EurJ Endocrinol2002 146 467-477. 

Type II diabetes mellitus since age 48. He admits that his diet prevents his diabetes from being well controlled. 

Raz, I., Eldor, R., and Naparstek, Y., Immune modulation for prevention of type I diabetes mellitus, Trends Biotechnol., 23, 128, 2005. 

Secondary prevention of type 1 diabetes mellitus stopping immune destruction and promoting (5-cell regeneration. Braz J Med Biol Res 2006 39 1271-1280. 

Older patients have predominantly Type 2 diabetes mellitus, which shares with Type 1 the risk for retinopathy, nephropathy and neuropathy, but carries a greater risk for macrovascular complications such as coronary artery disease, stroke and peripheral vascular disease. Many such patients have associated obesity, hypertension and hyperlipidemia, compounding the risk of cardiovascular disease. The goals of treatment of DM in the elderly are to decrease symptoms related to hyperglycaemia and to prevent long-term complications. Treatment of type 2 DM can improve prognosis. In the UKPDS trial, sulphonylureas, insulin, and metformin were all associated with a reduction in diabetes-related... 

Elliott, R. B., and Chase, H. P. (1991). Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34, 362-365. 

Thiazolidinediones have benefit in the prevention of type 2 diabetes. The Diabetes Prevention Trial reported a 75% reduction in diabetes incidence rate when troglitazone was administered to patients with prediabetes. Another study reported that troglitazone therapy significantly decreased the recurrence of diabetes mellitus in high-risk Hispanic women with a history of gestational diabetes. 

Chiasson JL et al Acarbose for prevention of type 2 diabetes mellitus The STOP-NIDDM randomized trial. Lancet 2002 359 2072. [PMID 12086760]... 

Delorme S, Chiasson J-L. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr Opinion Pharmacol 2005 5 184-9. 

Insulin-dependent diabetes mellitus (IDDM) is an example of a metabolic disease under active consideration for inducible gene therapy strategies. In this disorder, inflammatory cytokines have been shown to activate apoptosis in pancreatic beta cells. Experimental studies indicate that expression of insulinlike growth factor-1 (IGF-1) can prevent the cytokine-mediated destruction of beta cells of the pancreas (Giannoukakis et al., 2001). Regulated expression of IGF-1 in human pancreatic islets, to preserve beta cell function, may be a useful approach in the treatment of certain types of diabetes (Demeterco and Levine, 2001). 

Physical therapists and occupational therapists may help reinforce the importance of patient compliance during pharmacologic management of diabetes mellitus. Therapists can question whether patients have been taking their medications on a routine basis. Regular administration of insulin is essential in preventing a metabolic shift toward ketone body production and subsequent ketoacidosis, especially in patients with type 1 diabetes. In addition, therapists can help explain that adequate control of blood glucose not only prevents acute metabolic problems but also seems to decrease the incidence of the neurovascular complications. 

Henry, R. R. (1994). Prospects for Primary Prevention of Type II or Non-insulin— dependent Diabetes Mellitus. Diabetes Rev. Int. 3, 2-5. 

Hypertension and type 2 diabetes mellitus are frequent co-morbid conditions resulting in a very high risk population. ARBs - losartan as compared to the beta-blocker atenolol in the LIFE Study [8], candesartan as compared to the control therapies in the SCOPE [16] and CHARM [33] Studies, valsartan as compared to amlodipine in the VALUE Study [34] have been found to have beneficial effects in preventing the development of type 2 diabetes mellitus. 

As this patient has type 2 diabetes mellitus (a) Which drug/drug class mentioned above as standard secondary prevention may cause problems in this patient (b) What problems may be experienced in the use of this drug/drug class in a patient with type 2 diabetes mellitus (c) What alternative drug could you recommend ... 

As this patient has type 2 diabetes mellitus (a) Which drug/drug class mentioned above as standard secondary prevention may cause problems in this patient ... 

The European Health Food Manufacturers Federation restricts over-the-counter supplements to 500 mg per day (Shrimpton, 1997). Where niacin is being used to treat clinically significant hyperlipidemia, and in trials for the prevention of type I diabetes mellitus, a tentative upper limit has been set at 3 g per day (Knip et al., 2000). 

Schatz DA and Bingley PJ (2001) Update on major trials for the prevention of type 1 diabetes mellitus the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). Journal of Pediatrics Endocrinology and Metabolism 14(Suppl 1), 619-22. 

Cyclosporine is an important drug in preventing rejection after kidney, hver, heart and other organ transplantation (Haberal et al., 2004). Cyclosporine usually is combined with other immunosuppressives especially glucocorticoids and either azathioprine or mycophenolate mofedl and sirolimus (Krensky et al., 2005). In renal alio transplants it has improved graft acceptance in most clinics to 95 percent. In addition to its use in transplantation cyclosporine is used for the treatment of a number of autoimmune diseases. In autoimmune diseases, as might be anticipated, cyclosporine is most effective in those which are T cell mediated. These include several forms of psoriasis, rheumatoid arthritis refractive to all other therapy, uveitis, nephrotic syndrome and type I diabetes mellitus. 

Prevention of Type-I diabetes mellitus is also an important target. Here, methods must be improved for the detection of relevant markers appearing in the blood before the destruction of B-cells by the immune system. In this connection, further development of immunosuppressive agents with minimal side effects and high specifity against B-cell destruction is necessary. 

Approximately 5% to 10% of aU cases of diabetes mellitus are in this category. Patients usually have abrupt onset of symptoms (e.g., polyuria, polydipsia, and rapid weight loss). Patients have insulinopenia (a deficiency of insulin) caused by loss of pancreatic islet (3-ceUs and are dependent on insulin to sustain life and prevent ketosis. Most patients have antibodies that identify an autoimmune process (see later discussion) some patients have no evidence of autoimmunity and are classified as type 1 idiopathic. The peak incidence is in childliood and adolescence. Approximately 75% acquire the disease before age 30 years, but the onset in the remainder may occur at any age. Age at presentation is not a criterion for classification. 

American Diabetes Association. Prevention of type 1 diabetes mellitus. Diabetes Care 2003 26 Suppl 1 5140. 

Diabetes Prevention Trial—Type 1 Study Group. Effects of insuhn in relatives of patients with type 1 diabetes mellitus. N Engl f Med 2002 346 1685-91. 

Davies S, McLaren HJ, Hunnisett A, Howard M. Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients-implications for the prevention of cardiovascular disease and type II diabetes mellitus. Metabohsm 1997 46 469-73. 

---